Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 63 Leukemia, Myeloid, Acute 14 Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 11 Lymphoma, Non-Hodgkin 9 Lymphoma, Large B-Cell, Diffuse 9 Recurrence 8 Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Lymphoma 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Carcinoma, Small Cell 4 Ovarian Neoplasms 3 Leukemia 3 Hodgkin Disease 3 Extensive Stage Small Cell Lung Cancer 3 Small Cell Lung Cancer Extensive Stage 2 SCLC 2 Osteosarcoma 2 Neoplasm Metastasis 2 Lymphoma, B-Cell 2 Lymphatic Diseases 2 Immunoproliferative Disorders 2 Hematologic Diseases 2 Glioblastoma 2 Ependymoma 2 Advanced Solid Tumors 2 Widespread Small Cell Lung Cancer 1 Unresectable Locally Advanced or Metastatic Solid Tumors 1 Squamous Cell Carcinoma of Head and Neck 1

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Malignant Disease × Etoposide × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡